Perlegen Sciences, Inc., a molecular diagnostics company focused on the discovery and commercialization of clinically important human genetic variation, announced today the opening of its portfolio of patented technologies that together enable whole genome association studies capable of assessing an individual's predisposition to specific disease risks and treatment outcomes.

Perlegen Sciences, Inc. announced today that it has formed a personalized medicine collaboration with an undisclosed electronic medical records (EMR) provider to identify and develop genetic markers to help predict how patients are likely to respond to specific medical treatments.

Perlegen Sciences, Inc., and the SC Liver Research Consortium (SCLRC), announced today a collaboration to discover genetic variations that predict which patients with hepatitis C (HCV) are most likely to benefit from treatment.

Affymetrix Inc. (Nasdaq:AFFX) today reported its operating results for the fourth quarter and fiscal year ended December 31, 2007. Total revenue for the fourth quarter was $107.6 million, as compared to total revenue of $104.2 million in the fourth quarter of 2006.

The six-country International HapMap Consortium today made available to the public its second-generation map of human genetic variation. This new map contains three times the number of markers unveiled in the initial version, released in 2005.